| P/E (FY) | 22.0 | Sales (TTM) | SEK 469.0M |
| Earnings (TTM) | SEK 56.4M | ROE | 18.94% |
| Net Margin | 12.04% | ROIC | 31.37% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 31.17% | Sales Growth 3Y | 21.55% |
C-Rad AB (publ) develops, manufactures, and sells products and systems for radiotherapy in cancer treatment across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. Its offerings include the Catalyst family of surface-guided radiation therapy and patient-positioning solutions, the laser-based Sentinel 4DCT optical surface scanner, the cAutoVerify automation tool for patient identity validation and accessory tracking, and HIT laser positioning products, supported by training and service contracts. The company was incorporated in 2004 and is headquartered in Uppsala, Sweden.
| Market Cap | — | Trading Days | 4112 |
| 52W High | 39.40 |
| 52W Low | 24.60 |
| % Off High | −6.60% |
| YTD | 15.53% | 1Y | 4.27% |
| 3Y | 29.97% | 5Y | −38.99% |
| 10Y | 238.64% | Since incept. (ann.) | 4.42% |
| Ann. Volatility (1Y) | 41.75% | Ann. Volatility (3Y) | 38.65% |
| Sharpe (1Y) | 0.30 | Sharpe (3Y) | 0.43 |
| Max Drawdown (1Y) | −30.83% | Max Drawdown (3Y) | −49.03% |
| Beta (3Y, vs SPY) | 0.97 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| AMGN | AMGEN INC | $212.16B | 27.6 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| SYK | STRYKER CORP | $132.87B | 41.3 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| ISRG | INTUITIVE SURGICAL INC | $127.82B | 46.0 |
